Telesis Bio, Inc. Common Stock
TBIO
TBIO was delisted on the 27th of September, 2024.
43 hedge funds and large institutions have $76.8M invested in Telesis Bio, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 9 increasing their positions, 9 reducing their positions, and 17 closing their positions.
18% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 17
8% more funds holding
Funds holding: 40 → 43 (+3)
1.19% more ownership
Funds ownership: 22.38% → 23.57% (+1.2%)
0% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 9
45% less capital invested
Capital invested by funds: $139M → $76.8M (-$61.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OAM
Ophir Asset Management
Sydney,
Australia
|
+$9.32M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.34M |
| 3 |
AC
Armistice Capital
New York
|
+$4.74M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$2.59M |
| 5 |
BlackRock
New York
|
+$1.88M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MWNA
Marshall Wace North America
New York
|
-$5.16M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$5.11M |
| 3 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$4.4M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$2.2M |
| 5 |
Goldman Sachs
New York
|
-$1.47M |
TBIO Hedge Fund Activity: Q3 2021 in Review
43 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Telesis Bio, Inc. Common Stock (TBIO) for Q3 2021, worth a combined $76.8M — down 45% from $139M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new TBIO positions and 17 closed out — a net gain of 3 holders — while 9 added to existing stakes and 9 trimmed.
The largest buyer was Ophir Asset Management, opening a new position worth an estimated $9.32M. The largest seller was Marshall Wace North America, exiting entirely with an estimated $5.16M sold.
- 43 institutional investors held Telesis Bio, Inc. Common Stock (TBIO) as of Q3 2021, up from 40 in Q2 2021.
- Funds reported $76.8M of Telesis Bio, Inc. Common Stock stock for Q3 2021, down 45% quarter-over-quarter.
- 20 funds opened new Telesis Bio, Inc. Common Stock positions in Q3 2021 and 17 closed out, a net change of +3 holders.
- The largest Telesis Bio, Inc. Common Stock buyer in Q3 2021 was Ophir Asset Management, an estimated $9.32M added.
- The largest Telesis Bio, Inc. Common Stock seller in Q3 2021 was Marshall Wace North America, an estimated $5.16M sold.
Based on aggregated 13F filings for Q3 2021.